Abstract Treatment of BRAF-mutant melanoma with combined dabrafenib and trametinib,
which target RAF and the downstream MAP–ERK kinase (MEK) 1 and MEK2 kinases …

Selective RAF inhibitors have significant activity in patients with metastatic melanoma whose
tumors express BRAFV600E. However, not all patients respond equally well to treatment …

Metastatic melanoma remains an incurable disease for many patients due to the limited
success of targeted and immunotherapies. BRAF and MEK inhibitors reduce metastatic …

The receptor tyrosine kinase (RTK) MET represents a promising tumor target in a subset of
glioblastomas. Most RTK inhibitors available in the clinic today, including those inhibiting …

The BRAF inhibitor (BRAFi) treatment has led to impressive responses in BRAFV600E
mutation-positive melanomas, but responses are not durable in many patients. As most of …

Background Preclinical and clinical data suggest that combination of a BRAF and a MEK
inhibitor (BRAFi, MEKi) may increase the efficacy over BRAFi monotherapy in BRAF-mutant …

The MAPK pathway is frequently activated in many human cancers, particularly melanomas.
A single-nucleotide mutation in BRAF resulting in the substitution of glutamic acid for valine …

A newer generation of anti-cancer drugs targeting underlying somatic genetic driver events
have resulted in high single-agent or single-pathway response rates in selected patients, but …

Purpose: BRAF and MEK inhibitors (BRAFi and MEKi) are actively used for the treatment of
metastatic melanoma in patients with BRAFV600E mutation in their tumors. However, the …

Malignant melanoma is challenging to treat, and metastatic cases need chemotherapy
strategies. Targeted inhibition of commonly mutant BRAF V600E by inhibitors is efficient but …